Partnerships Archives

News and Trends 13 Mar 2023

Sanofi adds diabetes drug through Provention Bio $2.9B acquisition

Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc., for $25.00 per share in cash, representing an equity value of approximately $2.9 billion. The transaction adds […]

March 13, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 8 Mar 2023

Affibody and Chiesi Group to develop treatments for respiratory diseases

Affibody AB and Chiesi Farmaceutici S.p.A have announced a collaboration and licensing agreement to develop and commercialize innovative treatments for respiratory diseases using Affibody’s proprietary technology. Under the terms of the agreement, the parties will collaborate to progress up to three programs based on Affibody molecules against undisclosed targets for respiratory diseases. Chiesi will fund […]

March 8, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Mar 2023

Lilly to develop Confo pain drug

Confo Therapeutics, which works on the discovery of medicines targeting G-protein coupled receptors (GPCRs), has announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and back-up compounds. CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R) is currently in phase 1 clinical development. It represents a […]

March 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Mar 2023

Porton and DanausGT look to boost development of gene and cell therapy

Porton Advanced Solutions Ltd. and DanausGT Biotechnology Co., Ltd. have announced a strategic collaboration in gene and cell therapy pipelines to expedite the development of innovative therapeutics. As an end-to-end gene and cell therapy service provider, Porton Advanced CDMO offers solutions covering plasmids, cell therapy, gene therapy, oncolytic viruses, mRNA therapy, and bacterial therapy. DanausGT […]

March 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 2 Mar 2023

Partnership formed to develop miRNA to treat pancreatic cancer

RNA delivery and therapeutics company SiSaf Ltd is to collaborate with the University of Leipzig in Germany to develop targeted micro interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer. The collaboration will combine SiSaf’s work in RNA delivery using its Bio-Courier silicon-stabilized hybrid lipid nanoparticles (sshLNPs) and the […]

March 2, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 28 Feb 2023

Peter MacCallum Cancer Centre and Cartherics to work on CAR-T cell therapy for ovarian cancer

Peter MacCallum Cancer Centre (Peter Mac) in Australia and Cartherics Pty Ltd have entered into a collaborative development program agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment of ovarian cancer. The clinical trial to be conducted by Peter Mac will be the first time a CAR-T cell therapy product […]

February 28, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

Moderna and Life Edit Therapeutics look to speed up gene editing therapies

Moderna, Inc., a biotechnology company working on messenger RNA (mRNA) therapeutics and vaccines, and Life Edit Therapeutics Inc., an ElevateBio company focused on gene editing technologies and therapeutics, have announced a strategic research and development collaboration to discover and develop in vivo mRNA gene editing therapies. The partnership will combine Life Edit’s suite of proprietary […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 14 Feb 2023

Scancell looking to partner after positive COVID vaccine data

Scancell Holdings plc, which develops novel immunotherapies for the treatment of cancer and infectious disease, has announced preliminary immunogenicity data from its phase 1 COVIDITY clinical trial at the University of Cape Town (UCT) Lung Institute in South Africa. The objectives of the trial were to assess the safety and immunogenicity of two vaccine candidates, […]

February 14, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 14 Feb 2023

Syena created to deliver first-in-class TCR-NK cell therapy

Replay, a genome writing company reprogramming biology by writing and delivering big DNA, and The University of Texas MD Anderson Cancer Center, have launched Syena, a new oncology-focused product company pioneering T-cell receptor (TCR) natural killer (NK) cell therapies (TCR-NKs). Building on the intellectual property and technology from MD Anderson and Replay, Syena has the […]

February 14, 2023 - 4 minutesmins - By Jim Cornall

MDI Biosciences Cardiff University. Photo/Cardiff University

News and Trends 14 Feb 2023

Astex and Cardiff University Medicines Discovery Institute to collaborate on neurodegenerative diseases

Astex Pharmaceuticals (UK), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system and The Medicines Discovery Institute, Cardiff University (MDI) have entered into a multi-year, multi-million-pound drug discovery research collaboration, aimed to identify new drugs to treat neurodegenerative diseases. The collaboration […]

February 14, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 10 Feb 2023

Heartseed and Novo Nordisk dose first patient in heart failure cell therapy study

Heartseed Inc. and Novo Nordisk A/S say Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated four-week data on the patient, who lives with advanced heart failure and has given approval for […]

February 10, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Mnemo Therapeutics and Institut Curie studies lead to cancer-specific targets

Mnemo Therapeutics, a French biotechnology company developing immunotherapies, has announced publication of two scientific studies developed at Institut Curie, its closest academic collaborator, in the journal Science Immunology. The publications reveal TE-exon splicing junctions act as a source of novel recurrent, cancer-specific targets and have potential implications for developing more effective and less toxic immunotherapies. […]

February 7, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Partnerships

Sanofi adds diabetes drug through Provention Bio $2.9B acquisition

Affibody and Chiesi Group to develop treatments for respiratory diseases

Lilly to develop Confo pain drug

Porton and DanausGT look to boost development of gene and cell therapy

Partnership formed to develop miRNA to treat pancreatic cancer

Peter MacCallum Cancer Centre and Cartherics to work on CAR-T cell therapy for ovarian cancer

Moderna and Life Edit Therapeutics look to speed up gene editing therapies

Scancell looking to partner after positive COVID vaccine data

Syena created to deliver first-in-class TCR-NK cell therapy

Astex and Cardiff University Medicines Discovery Institute to collaborate on neurodegenerative diseases

Heartseed and Novo Nordisk dose first patient in heart failure cell therapy study

Mnemo Therapeutics and Institut Curie studies lead to cancer-specific targets

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!